Quantcast

FDA approves Bristol-Myers’s Opdivo for urothelial bladder cancer

U.S. Food and Drug Administration (FDA) has approved Bristol-Myers’s Opdivo injection, for treatment of urothelial carcinoma (mUC).

The bladder cancer is the fifth most diagnosed cancer, and urothelial carcinoma is the most common type of bladder cancer. Opdivo has already been approved for treating several types of cancer, including lung cancer, kidney cancer and advanced melanoma.

Bristol-Myers Squib in January posted fourth quarter net earnings of $1.1 billion, driven mostly by increased sales of Opdivo and Eliquis.

To remind, the New York headquartered company settled in January with Merck for infringing Opdivo patent to make a competitive drug Keytruda.

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.